Before approving a gummy shelf life, ask which product, package and data the date belongs to.
A default “24 months” is not a stability file. Use these ten questions to compare the evidence behind a dietary supplement gummy's proposed expiration or best-if-used-by date.
What FDA's dietary supplement guide actually says
The dietary supplement CGMP rule does not require an expiration, shelf or best-if-used-by date. FDA's compliance guide also says a company should have data to support any such date it places on the label. The guide does not create one universal stability schedule for every gummy, so the product owner and qualified quality team must define an appropriate, documented approach.
Ten questions that turn “shelf life” into reviewable evidence
1. Which exact formula?
Match active forms and amounts, gummy base, sweetener system, flavors, colors, acids, coatings and relevant processing assumptions. Evidence for a stock formula is not automatically evidence for a customized one.
2. Which commercial package?
Identify the bottle, pouch or blister; closure, seal, liner and any desiccant; count and headspace. The study package should be stated, not inferred from a product photo.
3. Which storage and distribution assumptions?
Record labeled storage conditions and the expected route to the customer. Ask how excursions, warehousing and transport risks are handled without treating a broad climate claim as proven.
4. What is the starting point?
Confirm batch or sample identity, manufacture and packaging dates, initial results and when the stability clock begins. A report needs traceability to the item actually placed on study.
5. Which attributes can end shelf life?
Define relevant identity, strength, composition, purity or contaminant criteria plus physical and sensory attributes important to the product. Do not assume potency is the only possible failure mode.
6. What are the acceptance criteria?
List the specification, limit or decision rule for each measured attribute. “Looks good” and “Pass” are not substitutes for defined criteria where quantitative results are expected. Use the product specification checklist to control the method, unit, sampling basis and disposition fields.
7. Are the methods appropriate?
Identify the method and laboratory for each test. Ask whether the method is suitable for the analyte in the finished gummy matrix and whether units and reporting limits fit the specification.
8. Which conditions and time points?
Review the written protocol, defined conditions, test intervals and rationale. Separate accelerated, intermediate and real-time observations instead of blending them into one unsupported date.
9. Which batches and samples?
Record study-batch scale, number of batches, sample selection and whether the batch and packaging are representative of the commercial product. Ask what uncertainty remains.
10. Who reviews trends and changes?
Define how unexpected results, excursions, packaging changes, supplier changes and formula revisions are assessed—and who can approve, shorten or extend the labeled date.
Do not accept these substitutions
| Claim being evaluated | Evidence question | Not an equivalent substitute |
|---|---|---|
| Finished potency through shelf life | Are results tied to the finished formula, package, time points and appropriate method? | An ingredient COA or day-zero finished-product result |
| Package protects the gummy | Was the commercial container-closure system identified in the evidence? | A generic packaging specification or supplier brochure |
| Texture remains acceptable | Are criteria and observations defined for the relevant product and conditions? | A fresh bench sample or undated photograph |
| Microbiological quality remains acceptable | Are applicable criteria, methods, sample identity and time points documented? | A facility certificate or unrelated product report |
| A new formula has the same shelf life | Was the impact of ingredient, process and package changes assessed? | Data for a similar-looking stock formula |
| Accelerated evidence supports launch assumptions | What does the written protocol support, what remains provisional and how is real-time evidence handled? | A verbal statement that accelerated time automatically equals calendar time |
Three packets, three different next questions
When a proposed gummy launch includes a shelf-life target, separate that target from the observations actually available. A report can be useful without answering the whole launch question. It can also be complete for one configuration and inapplicable to another.
The following packets are fictional reading exercises. The identifiers, time points and proposed duration are not real study results or a recommended study schedule. No pass or failure is assigned to an actual product.
Packet A: the package matches, but the observation window is shorter
The request names fictional formula F1, package P1 and a proposed 24-month date. The packet identifies F1/P1 and results at months 0, 3 and 6 under the stated study protocol.
Record what exists: observations through month 6 for the identified configuration and conditions. Do not rename the file “24-month validation” merely because 24 months appears in the project target. Also do not conclude that every shorter study is necessarily unusable: the relevant professionals may assess other evidence and a scientifically justified approach, which this packet alone does not describe.
Next question: “Which documented rationale and additional evidence support the proposed date? Are later observations completed but absent from this packet, ongoing, planned or unavailable?”
Packet B: the product name matches, but the package is different
The proposed configuration uses package P2. The report refers to P1. A familiar brand name and an unchanged serving description do not resolve that difference.
Record a scope mismatch. Ask for an identified comparison of P1 and P2 and an assessment of whether the evidence remains applicable. Do not assume either that the old data transfers automatically or that every package change requires a completely new study. The decision needs the actual changed attributes and relevant rationale.
Next question: “What exact package attributes changed, and what supports applying the existing evidence to P2?”
Packet C: the summary says “stable,” but the decision basis is missing
The packet includes an undated summary and a product photograph. It does not identify the study lot, protocol, time points or acceptance criteria.
Record the summary as an unverified lead to further evidence, not as a completed study. A photograph may document an appearance observation if properly identified; it cannot supply missing measurements or traceability by itself.
Next question: “Which controlled study reference, identified samples and results sit behind this summary?”
Copy this scope ledger
| Field | What the launch request proposes | What the packet actually identifies | Remaining decision |
|---|---|---|---|
| Product/formula version | Enter reference | Enter reference or unknown | Same / different / unresolved |
| Package system | Enter configuration | Enter tested configuration | Applicable / assessment needed |
| Study lot and scale | Enter intended basis | Enter reported basis | Representativeness to review |
| Conditions and protocol | Enter intended assumptions | Enter reported conditions | Relationship to explain |
| Time coverage | Enter proposed duration | Enter actual time points | Supporting rationale to review |
| Attributes and criteria | Enter the decision requirements | Enter measured scope | Untested or missing items |
| Current evidence state | Target | Observed / ongoing / summary only | Next document or assessment |
The ledger should contain references and scope, not confidential formulations or copied private reports. Preserve the distinction between accelerated and real-time evidence when describing the protocol; do not apply an automatic calendar conversion that the evidence does not establish.
FDA's dietary-supplement CGMP guide says the rule does not require an expiration date, but that a date placed on a label should have supporting data. The guide does not supply a universal 24-month gummy approval. FDA guide
Use the result to narrow the project discussion
The three packet states are not supplier scores. A clearly documented six-month observation may be more interpretable than an impressive but unidentified summary, while still being insufficient on its own for a particular decision. Keep both the useful observation and its limits visible.
Use the packaging change-control guide for P1-to-P2 questions and the COA guide for document layers.
Ask for a one-page stability evidence map before the RFQ is final
The map does not need to expose proprietary formulation details. It should identify the product or formula family, commercial package, study owner, protocol status, study conditions, time points, attributes, acceptance criteria, methods, batch coverage, available results and open decisions. Mark each statement as target, preliminary evidence, ongoing evidence or completed evidence.
This also makes quotes more comparable. One manufacturer may price only release testing, another may include protocol development or scheduled time-point testing, and a third may expect the brand to commission external work. The commercial proposal should say who owns each activity, report and decision.
Reserve samples are related—but they are not the stability study
FDA's dietary supplement CGMP guide says reserve samples of distributed packaged and labeled supplements must use the same container-closure system, be identified by batch, lot or control number, and be retained for one year past the shelf-life date when dating is used—or for two years after distribution of the last associated batch when it is not. Reserve samples support investigations; their existence does not by itself prove the labeled shelf life.
How Sucotond USA handles the first conversation
Sucotond USA coordinates U.S. sales and project requirements with the Guangzhou manufacturing facility. Share the target formula, serving, package, destination, proposed date and required attributes. The probiotic page connects strain and CFU timing; the mushroom page connects species and marker method; the omega-3 page connects source, EPA/DHA basis and oxidation methods; and the inositol page connects named isomers, individual amounts, matrix, method and commercial package. We can organize open questions for factory review, but a preliminary discussion is not a shelf-life approval or promise. Any public or commercial statement must be tied to the approved product, package and evidence available for that project.
COA and batch-records checklist
Separate ingredient, manufacturing, finished-product and stability documents before supplier approval.
Use checklist →Manufacturing feasibility checklist
Define serving design, gummy base, package, testing, volume and decision requirements before an RFQ.
Use checklist →Frequently asked questions
Does FDA require an expiration date on a dietary supplement?
FDA's dietary supplement CGMP compliance guide says the rule does not require an expiration, shelf or best-if-used-by date. The same guide says a company should have data to support any such date it places on a product label.
Is a release COA enough to support a gummy's shelf life?
No. A release COA reports results for an identified sample at a point in time. Shelf-life support needs evidence tied to the product, package, storage assumptions, time points, methods and acceptance criteria.
Can stability data for one package support a different bottle or pouch?
Not automatically. The evidence should identify the tested container-closure system. A package change needs an assessment of whether the existing evidence still applies and what additional work is needed. Use the packaging change-control checklist to compare the exact old and new configurations.
Does accelerated testing equal completed real-time shelf-life evidence?
No. They are different evidence types. Buyers should ask what each study is designed to support, which assumptions are provisional and how ongoing or completed real-time evidence affects the labeled date.
Official references
This checklist is a procurement and project-planning aid, not legal, scientific or regulatory advice. The appropriate evidence plan depends on the product and should be reviewed by qualified professionals.
Have a target shelf life and package to evaluate?
Send the non-confidential formula, serving, package, market and testing requirements. Our Brooklyn team will organize the questions for factory review.
Start a Project Review